<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5311">
  <stage>Registered</stage>
  <submitdate>20/10/2015</submitdate>
  <approvaldate>20/10/2015</approvaldate>
  <nctid>NCT02582632</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Na誰ve Hepatitis C Virus Genotype 1b-Infected Adults</studytitle>
    <scientifictitle>An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Na誰ve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)</scientifictitle>
    <utrn />
    <trialacronym>GARNET</trialacronym>
    <secondaryid>2015-003370-33</secondaryid>
    <secondaryid>M15-684</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C Infection</healthcondition>
    <healthcondition>Hepatitis C Virus</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ombitasvir/Paritaprevir/Ritonavir
Treatment: drugs - dasabuvir

Experimental: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir - Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks


Treatment: drugs: Ombitasvir/Paritaprevir/Ritonavir
Tablet

Treatment: drugs: dasabuvir
Tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of participants who achieve sustained virologic response 12 weeks post-treatment (SVR12) - Hepatitis c virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification.</outcome>
      <timepoint>12 weeks after the last actual dose of study drug</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with virologic failure during treatment - The percentage of participants with confirmed &gt;=1 log10 IU/mL increase from nadir in HCV RNA at any time point during treatment or with confirmed, quantifiable HCV RNA among participants with previous unquantifiable HCV RNA during treatment; or failure to suppress during treatment with at least 6 weeks of treatment.</outcome>
      <timepoint>Up to 8 weeks while on treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with post-treatment relapse - The percentage of participants with confirmed, quantifiable HCV RNA among participants with previous unquantifiable HCV RNA at the end of treatment.</outcome>
      <timepoint>Up to 12 weeks after last dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of female participants who achieve sustained virologic response 12 (SVR12) weeks post-treatment - HCV RNA levels less than the lower limit of quantification</outcome>
      <timepoint>12 weeks after the last actual dose of study drug</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of participants with low baseline viral load who achieve sustained virologic response 12 (SVR12) weeks post-treatment - HCV RNA levels less than the lower limit of quantification.</outcome>
      <timepoint>Baseline and 12 weeks after the last actual dose of study drug</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Chronic HCV infection at Screening.

          2. Screening laboratory result indicating HCV genotype 1b infection.

          3. Treatment-na誰ve and non-cirrhotic.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. HCV genotype or subtype other than GT1b.

          2. Positive test result for Hepatitis B surface antigen (HbsAg) or confirmed positive
             anti-HIV antibody (HIV Ab) (test).

          3. Any current or past clinical evidence of cirrhosis.

          4. Screening laboratory analyses that shows abnormal results.

          5. Clinically significant abnormalities or co-morbidities, other than HCV infection that
             make the participant an unsuitable candidate for this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>166</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 145473 - Adelaide</hospital>
    <hospital>Site Reference ID/Investigator# 145471 - Westmead</hospital>
    <hospital>Site Reference ID/Investigator# 145472 - Woolloongabba, Brisbane</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4102 - Woolloongabba, Brisbane</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Toronto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Winnipeg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseilles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt am Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Portsmouth, Hampshire</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and
      dasabuvir administered for 8 weeks in treatment-na誰ve participants with genotype 1b hepatitis
      C virus (HCV).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02582632</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Emily Dumas, PhD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>